Alphabiome Secures $8M Seed Funding to Revolutionize Microbiome-Driven Precision Medicine
Alphabiome, a pioneering company in microbiome research, has raised $8 million in seed funding from AIX Ventures and other investors. With a focus on combining advanced AI and microbiome analytics, Alphabiome is poised to revolutionize precision medicine by identifying previously uncharacterized microbial DNA patterns and predicting drug efficacy with exceptional accuracy.
